Caffeine to improve oxygen levels in mildly preterm babies (Latte Dosage Trial)

Phase 2

Completed

• Conditions: Intermittent hypoxaemia; Reproductive Health and Childbirth - Complications of newborn; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12618001745235
• Lead Sponsor: The University of Auckland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-10-24
• Study Completion: 2021-12-17
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 132

Inclusion Criteria

Infants:
Infants born between 34+0 – 36+6 weeks’ GA without contradiction to caffeine treatment and are 72 hours of age or less.

Mothers:
Mother's who have given birth to an infant who is of 34+0 - 36+6 GA

Exclusion Criteria

Infants:
•Major congenital abnormality
•Minor congenital abnormality likely to affect respiration, growth or development
•Previous caffeine treatment
•Renal or hepatic impairment
•Tachyarrhythmia
•Seizures
•Hypoxic ischaemic encephalopathy
•Residing outside of the Auckland DHB regions

Mothers:
Mother's who have given birth to an infant who has any of the exclusion criteria listed above

Study & Design

• Study Type: Interventional
• Study Design: Not specified